News AZ makes case for hypophosphatasia drug after phase 3 miss AstraZeneca has high sales expectations for HPP therapy efzimfotase alfa, but will the data support the broad label needed to unlock its potential?
News AZ considers filings for long-acting Strensiq follow-up AstraZeneca's long-acting Strensiq follow-up efzimfotase alfa has hit the mark in children with rare disease HPP, but the data in adults is unclear.
News Alexion lambasts NICE over rare disease ruling Watchdog accused of ignoring stakeholder consensus and call for negotiations
News Rare disease drug Strensiq too expensive, says NICE Alexion's new rare disease treatment Strensiq has been rejected by England's health watchdog NICE in draft guidance.
R&D Boosting biotech in Basel – with Valentina Francia pharmaphorum speaks with Valentina Francia from Basel Area Business and Innovation about why many life sciences startups are finding success in Basel.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.